Why ADC Linker Payload Design Is The Real Differentiator In ADC Success

Antibody-drug conjugates are often viewed as targeted missiles, yet the ultimate clinical success of these molecules hinges directly on the chemistry connecting the targeting antibody to its cytotoxic payload. While the antibody directs location, the linker-payload architecture governs circulatory stability, intracellular release dynamics, bystander killing efficacy, and overall systemic toxicity. Balancing these factors requires addressing drug-to-antibody ratio variations and hydrophobicity challenges early in design, preventing rapid plasma clearance or aggregation before reaching the tumor microenvironment. Treating the linker-payload as an integrated intermediate—rather than an assembly of separate components—helps preserve therapeutic indexes and accelerates translation into stable, manufacturable clinical candidates.

Read the full article to discover critical strategies for optimizing candidate selection and streamlining bioconjugation workflows.